Vincristine: Beyond on anticancer treatment

Abstract

Vincristine is a chemotherapeutic agent that is a component of many combination regimens for a variety of malignancies, including several common pediatric tumors.78% of patients with advanced malignant disease were treated with vincristine, an alkaloid derived from vinca rosea Linn, 59% of these survived from the beginning of treatment and could be evaluated. Favourable responses were seen in patients with Hodking's disease, reticulum cell sarcoma, lymphosarcoma, carcinoma of the breast, acute leukemia and choriocarcinoma. Toxic include a high incidence of alopecia and neurologic complications. Vincristine treatment is limited by a progressive sensorimotor peripheral neuropathy. Vincristine-induced peripheral neuropathy (VIPN) is particularly challenging to detect and monitor in pediatric patients, in whom the side effect can diminish long term quality of life. Further research is needed to predict, prevent, and treat disease to maximize therapeutic benefit and avoid unnecessary toxicity from vincristine treatment.

Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine

“…Crude methanolic extracts of vincristine in combination therapy with conferone from Ferula schtschurowskiana increased its cytotoxicity in the cancer cells. Conferone competitively binds to P-gp transporters, decreases the vincristine resistance, thus, and enhances vincristine cytotoxicity [ 119 , 120 ]. In-vitro and in vivo clinical studies of vincristine sulphate demonstrated an increase in cell death when administered intraperitoneally.…”

Effect of vincristine on intraocular pressure and tear fluid oxidative stress biomarkers in canine transmissible venereal tumor

“…1,2 However, the oculo-visual system has a potentially high sensitivity to toxic substances. 3,4 In this way, understanding ocular complications will help veterinarians and oncologists recognize them early and intervene before blindness occurs. Anticipating various treatment-related toxicities may allow pharmacists to develop intervention strategies that could minimize or eliminate an expected side effect.…”

“…Neurotoxicity is a common and dose-limiting adverse effect of vincristine in medical medicine, which usually occurs as cranial nerve palsy, and optic neuropathy/atrophy. 4,10 Depolarization of neurotubules by vincristine results in neurofibrillary degeneration and impairment of axonal transport. Blindness is a rare central neurotoxicity of vincristine therapy, with 11 reported cases in humans.…”

“…According to most studies, cancer chemotherapeutic drugs rarely cause ocular side effects 1,2 . However, the oculo‐visual system has a potentially high sensitivity to toxic substances 3,4 . In this way, understanding ocular complications will help veterinarians and oncologists recognize them early and intervene before blindness occurs.…”

“…Vincristine is a natural alkaloid that binds with tubulin dimers, inhibiting the assembly of microtubules in the mitotic spindle at the metaphase stage of cell division. Neurotoxicity is a common and dose‐limiting adverse effect of vincristine in medical medicine, which usually occurs as cranial nerve palsy, and optic neuropathy/atrophy 4,10 . Depolarization of neurotubules by vincristine results in neurofibrillary degeneration and impairment of axonal transport.…”